HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis.

AbstractBACKGROUND AND AIMS:
Detection of autoantibodies is a mainstay of diagnosing autoimmune hepatitis (AIH). However, conventional autoantibodies for the workup of AIH lack either sensitivity or specificity, leading to substantial diagnostic uncertainty. We aimed to identify more accurate serological markers of AIH with a protein macroarray.
APPROACH AND RESULTS:
During the search for more-precise autoantibodies to distinguish AIH from non-AIH liver diseases (non-AIH-LD), IgG antibodies with binding capacities to many human and foreign proteins were identified with a protein macroarray and confirmed with solid-phase ELISAs in AIH patients. Subsequently, polyreactive IgG (pIgG) was exemplarily quantified by reactivity against human huntingtin-interacting protein 1-related protein in bovine serum albumin blocked ELISA (HIP1R/BSA). The diagnostic fidelity of HIP1R/BSA binding pIgG to diagnose AIH was assessed in a retrospective training, a retrospective multicenter validation, and a prospective validation cohort in cryoconserved samples from 1,568 adults from 10 centers from eight countries. Reactivity against HIP1R/BSA had a 25% and 14% higher specificity to diagnose AIH than conventional antinuclear and antismooth muscle antibodies, a significantly higher sensitivity than liver kidney microsomal antibodies and antisoluble liver antigen/liver pancreas antigen, and a 12%-20% higher accuracy than conventional autoantibodies. Importantly, HIP1R/BSA reactivity was present in up to 88% of patients with seronegative AIH and in up to 71% of AIH patients with normal IgG levels. Under therapy, pIgG returns to background levels of non-AIH-LD.
CONCLUSIONS:
pIgG could be used as a promising marker to improve the diagnostic workup of liver diseases with a higher specificity for AIH compared to conventional autoantibodies and a utility in autoantibody-negative AIH. Likewise, pIgG could be a major source of assay interference in untreated AIH.
AuthorsRichard Taubert, Bastian Engel, Jana Diestelhorst, Katharina L Hupa-Breier, Patrick Behrendt, Niklas T Baerlecken, Kurt-Wolfram Sühs, Maciej K Janik, Kalliopi Zachou, Marcial Sebode, Christoph Schramm, María-Carlota Londoño, Sarah Habes, UK-AIH Consortium, Ye H Oo, Claudine Lalanne, Simon Pape, Maren Schubert, Michael Hust, Stefan Dübel, Mario Thevis, Danny Jonigk, Julia Beimdiek, Falk F R Buettner, Joost P H Drenth, Luigi Muratori, David H Adams, Jessica K Dyson, Amédée Renand, Isabel Graupera, Ansgar W Lohse, George N Dalekos, Piotr Milkiewicz, Martin Stangel, Benjamin Maasoumy, Torsten Witte, Heiner Wedemeyer, Michael P Manns, Elmar Jaeckel
JournalHepatology (Baltimore, Md.) (Hepatology) Vol. 75 Issue 1 Pg. 13-27 (01 2022) ISSN: 1527-3350 [Electronic] United States
PMID34473365 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Copyright© 2021 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.
Chemical References
  • Autoantibodies
  • Biomarkers
  • Immunoglobulin G
Topics
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Autoantibodies (blood)
  • Biomarkers (blood)
  • Diagnosis, Differential
  • Female
  • Hepatitis, Autoimmune (blood, diagnosis, immunology)
  • Humans
  • Immunoglobulin G (blood)
  • Male
  • Middle Aged
  • Retrospective Studies
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: